Search Results - "Negoita, Manuela"

A Controlled Trial of Renal Denervation for Resistant Hypertension by Bhatt, Deepak L, Kandzari, David E, O'Neill, William W, D'Agostino, Ralph, Flack, John M, Katzen, Barry T, Leon, Martin B, Liu, Minglei, Mauri, Laura, Negoita, Manuela, Cohen, Sidney A, Oparil, Suzanne, Rocha-Singh, Krishna, Townsend, Raymond R, Bakris, George L

“…In this large trial, denervation of the kidneys with use of a radiofrequency ablation catheter in the renal arteries had no significant effect on blood…”
Get full text

SYMPLICITY HTN-Japan　– First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients by Kario, Kazuomi, Ogawa, Hisao, Okumura, Ken, Okura, Takafumi, Saito, Shigeru, Ueno, Takafumi, Haskin, Russel, Negoita, Manuela, Shimada, Kazuyuki, on behalf of the SYMPLICITY HTN-Japan Investigators

“…Background:SYMPLICITY HTN-Japan is a prospective, randomized, controlled trial comparing renal artery denervation (RDN) with standard pharmacotherapy for…”
Get full text

Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents by Serruys, Patrick W, Silber, Sigmund, Garg, Scot, van Geuns, Robert Jan, Richardt, Gert, Buszman, Pawel E, Kelbæk, Henning, van Boven, Adrianus Johannes, Hofma, Sjoerd H, Linke, Axel, Klauss, Volker, Wijns, William, Macaya, Carlos, Garot, Philippe, DiMario, Carlo, Manoharan, Ganesh, Kornowski, Ran, Ischinger, Thomas, Bartorelli, Antonio, Ronden, Jacintha, Bressers, Marco, Gobbens, Pierre, Negoita, Manuela, van Leeuwen, Frank, Windecker, Stephan

“…This study compared two new-generation drug-eluting coronary stents that release zotarolimus or everolimus. Clinical and angiographic outcomes were similar…”
Get full text

Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial by Kandzari, David E., Bhatt, Deepak L., Sobotka, Paul A., O'Neill, William W., Esler, Murray, Flack, John M., Katzen, Barry T., Leon, Martin B., Massaro, Joseph M., Negoita, Manuela, Oparil, Suzanne, Rocha‐Singh, Krishna, Straley, Craig, Townsend, Raymond R., Bakris, George

“…Hypertension represents a significant global public health concern, contributing to vascular and renal morbidity, cardiovascular mortality, and economic…”
Get full text

Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions by Nikolsky, Eugenia, Mehran, Roxana, Lasic, Zoran, Mintz, Gary S., Lansky, Alexandra J., Na, Yingbo, Pocock, Stuart, Negoita, Manuela, Moussa, Issam, Stone, Gregg W., Moses, Jeffrey W., Leon, Martin B., Dangas, George

“…Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. The relationship between low hematocrit and contrast-induced…”
Get full text

12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension by Bakris, George L., MD, Townsend, Raymond R., MD, Flack, John M., MD, MPH, Brar, Sandeep, MD, Cohen, Sidney A., MD, PhD, D’Agostino, Ralph, PhD, Kandzari, David E., MD, Katzen, Barry T., MD, Leon, Martin B., MD, Mauri, Laura, MD, MSc, Negoita, Manuela, MD, O’Neill, William W, Oparil, Suzanne, MD, Rocha-Singh, Krishna, MD, Bhatt, Deepak L., MD, MPH

“…Abstract Background Results of the SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial confirmed the safety but not the…”
Get full text

Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure by Bakris, George L., MD, Townsend, Raymond R., MD, Liu, Minglei, PhD, Cohen, Sidney A., MD, PhD, D’Agostino, Ralph, PhD, Flack, John M., MD, MPH, Kandzari, David E., MD, Katzen, Barry T., MD, Leon, Martin B., MD, Mauri, Laura, MD, MSc, Negoita, Manuela, MD, O’Neill, William W., MD, Oparil, Suzanne, MD, Rocha-Singh, Krishna, MD, Bhatt, Deepak L., MD, MPH

“…Abstract Background Prior studies of catheter-based renal artery denervation have not systematically performed ambulatory blood pressure monitoring (ABPM) to…”
Get full text

Rationale and design of the clinical evaluation of the Resolute Zotarolimus-Eluting Coronary Stent System in the treatment of de novo lesions in native coronary arteries (the RESOLUTE US clinical trial) by Mauri, Laura, MD, MSc, Leon, Martin B., MD, Yeung, Alan C., MD, Negoita, Manuela, MD, Keyes, Michelle J., PhD, Massaro, Joseph M., PhD

“…Background Drug-eluting stents (DES) are commonly used to treat obstructive coronary disease and avoid restenosis. Newer DES have been developed to improve…”
Get full text

Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction by Nikolsky, Eugenia, Stone, Gregg W., Grines, Cindy L., Cox, David A., Garcia, Eulogio, Tcheng, James E., Griffin, John J., Guagliumi, Giulio, Stuckey, Thomas, Turco, Mark, Negoita, Manuela, Lansky, Alexandra J., Mehran, Roxana

“…The prognostic importance of obesity after primary percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (AMI) is unknown. We…”
Get full text

Clinical and Angiographic Results With the Next-Generation Resolute Stent System by Meredith, Ian T., MBBS, PhD, Worthley, Stephen, MBBS, Whitbourn, Robert, MBBS, Walters, Darren L., MBBS, McClean, Dougal, MD, Horrigan, Mark, MBBS, Popma, Jeffrey J., MD, Cutlip, Donald E., MD, DePaoli, Ann, DVM, Negoita, Manuela, MD, Fitzgerald, Peter J., MD

“…Objectives The RESOLUTE trial examined the safety and efficacy of a next-generation zotarolimus-eluting coronary stent, Resolute (Medtronic CardioVascular…”
Get full text

Prognostic significance of cerebrovascular and peripheral arterial disease in patients having percutaneous coronary interventions by Nikolsky, Eugenia, Mehran, Roxana, Dangas, George D., Lasic, Zoran, Mintz, Gary S., Negoita, Manuela, Lansky, Alexandra J., Stone, Gregg W., Moussa, Issam, Iyer, Sriram, Na, Yingbo, Moses, Jeffrey W., Leon, Martin B.

“…This study shows that cerebrovascular and peripheral arterial diseases frequently co-exist in patients with coronary artery disease who undergo percutaneous…”
Get full text

First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension by Böhm, Michael, Mahfoud, Felix, Ukena, Christian, Hoppe, Uta C, Narkiewicz, Krzysztof, Negoita, Manuela, Ruilope, Luis, Schlaich, Markus P, Schmieder, Roland E, Whitbourn, Robert, Williams, Bryan, Zeymer, Uwe, Zirlik, Andreas, Mancia, Giuseppe

“…This study aimed to assess the safety and effectiveness of renal denervation using the Symplicity system in real-world patients with uncontrolled hypertension…”
Get full text

Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3 by Bakris, George L, Townsend, Raymond R, Liu, Minglei, Cohen, Sidney A, D'Agostino, Ralph, Flack, John M, Kandzari, David E, Katzen, Barry T, Leon, Martin B, Mauri, Laura, Negoita, Manuela, O'Neill, William W, Oparil, Suzanne, Rocha-Singh, Krishna, Bhatt, Deepak L

“…Prior studies of catheter-based renal artery denervation have not systematically performed ambulatory blood pressure monitoring (ABPM) to assess the efficacy…”
Get full text

Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial by Feres, Fausto, Costa, Ricardo A, Abizaid, Alexandre, Leon, Martin B, Marin-Neto, J. Antônio, Botelho, Roberto V, King, Spencer B, Negoita, Manuela, Liu, Minglei, de Paula, J. Eduardo T, Mangione, José A, Meireles, George X, Castello, Hélio J, Nicolela, Eduardo L, Perin, Marco A, Devito, Fernando S, Labrunie, André, Salvadori, Décio, Gusmão, Marcos, Staico, Rodolfo, Costa, J. Ribamar, de Castro, Juliana P, Abizaid, Andrea S, Bhatt, Deepak L

“…IMPORTANCE The current recommendation is for at least 12 months of dual antiplatelet therapy after implantation of a drug-eluting stent. However, the optimal…”
Get full text

Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents: Final 5-Year Report of the RESOLUTE All-Comers Trial by Iqbal, Javaid, Serruys, Patrick W, Silber, Sigmund, Kelbaek, Henning, Richardt, Gert, Morel, Marie-Angele, Negoita, Manuela, Buszman, Pawel E, Windecker, Stephan

“…BACKGROUND—Newer-generation drug-eluting stents that release zotarolimus or everolimus have been shown to be superior to the first-generation drug-eluting…”
Get full text

12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial by Bakris, George L, Townsend, Raymond R, Flack, John M, Brar, Sandeep, Cohen, Sidney A, D'Agostino, Ralph, Kandzari, David E, Katzen, Barry T, Leon, Martin B, Mauri, Laura, Negoita, Manuela, O'Neill, William W, Oparil, Suzanne, Rocha-Singh, Krishna, Bhatt, Deepak L

“…Results of the SYMPLICITY HTN-3 (Renal Denervation in Patients With Uncontrolled Hypertension) trial confirmed the safety but not the efficacy of renal…”
Get full text

Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial by Weber, Thomas, Wassertheurer, Siegfried, Mayer, Christopher C., Hametner, Bernhard, Danninger, Kathrin, Townsend, Raymond R., Mahfoud, Felix, Kario, Kazuomi, Fahy, Martin, DeBruin, Vanessa, Peterson, Nicole, Negoita, Manuela, Weber, Michael A., Kandzari, David E., Schmieder, Roland E., Tsioufis, Konstantinos P., Binder, Ronald K., Böhm, Michael

“…Renal denervation (RDN) lowers blood pressure (BP), but BP response is variable in individual patients. We investigated whether measures of pulsatile…”
Get full text

NONINVASIVE 24-HOUR HEMODYNAMICS PREDICT BLOOD PRESSURE RESPONSE TO RENAL DENERVATION IN THE SPYRAL HTN-OFF MED PILOT AND PIVOTAL TRIALS by Weber, Thomas, Wassertheurer, Siegfried, Mayer, Christopher C., Hametner, Bernhard, Townsend, Raymond R., Mahfoud, Felix, Kario, Kazuomi, Fahy, Martin, Debruin, Vanessa, Peterson, Nicole, Negoita, Manuela, Weber, Michael A., Boehm, Michael

“…Objective: To investigate whether hemodynamic measures obtained during regular 24-hour blood pressure (BP) monitoring may predict BP response to renal…”
Get full text

Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial by Weber, Thomas, Wassertheurer, Siegfried, Mayer, Christopher C., Hametner, Bernhard, Danninger, Kathrin, Townsend, Raymond R., Mahfoud, Felix, Kario, Kazuomi, Fahy, Martin, DeBruin, Vanessa, Peterson, Nicole, Negoita, Manuela, Weber, Michael A., Kandzari, David E., Schmieder, Roland E., Tsioufis, Konstantinos P., Binder, Ronald K., Böhm, Michael

Get full text

The rise, fall, and possible resurrection of renal denervation by Gulati, Rajiv, Raphael, Claire E., Negoita, Manuela, Pocock, Stuart J., Gersh, Bernard J.

“…Renal denervation for the treatment of drug-resistant hypertension has been studied extensively in the past few years. Although early trials reported dramatic…”
Get full text